-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhelion unit Filament Health ships PEX010 for Bruyère’s Phase 3 microdose psilocybin trial

PUBT·09/21/2026 11:50:26
Listen to the news
Rhelion unit Filament Health ships PEX010 for Bruyère’s Phase 3 microdose psilocybin trial
  • Rhelion Life Sciences’ wholly owned Filament Health shipped PEX010 botanical psilocybin to Bruyère Health Research Institute for a Phase 3 trial.
  • PSYCHED-PAL Phase 3 is a double-blind, placebo-controlled study in palliative care, targeting 120 participants across seven Canadian sites.
  • Filament supplies PEX010 as a GMP-manufactured, standardized drug candidate; Rhelion completed its acquisition of Filament on April 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609210749NEWSFILECNPR____20260921_315164_1) on September 21, 2026, and is solely responsible for the information contained therein.